Patents by Inventor Winton Dennis Jones

Winton Dennis Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7655641
    Abstract: The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: February 2, 2010
    Assignee: Eli Lilly and Company
    Inventors: Scott Eugene Conner, Lynn Stacy Gossett, Jonathan Edward Green, Winton Dennis Jones, Jr., Nathan Bryan Mantlo, Donald Paul Matthews, Daniel Ray Mayhugh, Daryl Lynn Smith, Jennifer Ann Vance, Xiaodong Wang, Alan M Warshawsky, Leonard Larry Winneroski, Jr., Yanping Xu, Guoxin Zhu
  • Patent number: 7595339
    Abstract: Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: September 29, 2009
    Assignee: Eli Lilly and Company
    Inventors: Jennifer Rebecca Allen, Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, George Stuart Gregory, Stephen Andrew Hitchcock, Paul J. Hoogestraat, Winton Dennis Jones, Jr., Daryl Lynn Smith
  • Publication number: 20080287504
    Abstract: Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.
    Type: Application
    Filed: August 17, 2007
    Publication date: November 20, 2008
    Inventors: Jennifer Rebecca Allen, Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, George Stuart Gregory, Stephen Andrew Hitchcock, Paul J. Hoogestraat, Winton Dennis Jones, JR., Daryl Lynn Smith
  • Publication number: 20080167310
    Abstract: The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.
    Type: Application
    Filed: October 3, 2007
    Publication date: July 10, 2008
    Inventors: Lynn Stacy Gossett, Jonathan Edward Green, James Robert Henry, Winton Dennis Jones, Donald Paul Matthews, Quanrong Shen, Daryl Lynn Smith, Jennifer Ann Vance, Alan M. Warshawsky, Maria Rosario Gonzalez-Garcia
  • Patent number: 7282501
    Abstract: The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: October 16, 2007
    Assignee: Eli Lilly and Company
    Inventors: Lynn Stacy Gossett, Jonathan Edward Green, James Robert Henry, Winton Dennis Jones, Donald Paul Matthews, Quanrong Shen, Daryl Lynn Smith, Jennifer Ann Vance, Alan M. Warshawsky
  • Patent number: 7276516
    Abstract: Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: October 2, 2007
    Assignee: Eli Lilly and Company
    Inventors: Jennifer Rebecca Allen, Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, George Stuart Gregory, Steven Andrew Hitchcock, Paul J. Hoogestraat, Winton Dennis Jones, Jr., Daryl Lynn Smith
  • Patent number: 7034045
    Abstract: The present invention provides certain monofluoroalkyl derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: April 17, 2000
    Date of Patent: April 25, 2006
    Assignee: Eli Lilly and Company
    Inventors: David Michael Bender, Buddy Eugene Cantrell, Andrew Hendley Fray, Winton Dennis Jones, William David Miller, David Mitchell, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Patent number: 6911476
    Abstract: The present invention provides certain sulfonamide derivatives useful for potentiating glutamate receptor function in a patient and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: February 26, 2001
    Date of Patent: June 28, 2005
    Assignee: Eli Lilly and Company
    Inventors: Joshua Zwick Davison, Winton Dennis Jones, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Patent number: 6900353
    Abstract: The present invention provides compounds of formula (I): useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: May 31, 2005
    Assignee: Eli Lilly and Company
    Inventors: Buddy Eugene Cantrell, Winton Dennis Jones, Jr., Timothy Alan Shepherd, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Publication number: 20040198833
    Abstract: The present invention provides compounds of formula (I), useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Application
    Filed: January 30, 2003
    Publication date: October 7, 2004
    Inventors: David Michael Bender, Scott Louis Forman, Winton Dennis Jones, Daryl Lynn Smith, Dennis Michael Zimmermann
  • Publication number: 20040097499
    Abstract: The present invention provides certain amide, carbamate and urea derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Application
    Filed: July 3, 2003
    Publication date: May 20, 2004
    Inventors: MacKlin Brian Arnold, David Michael Bender, Thomas John Bleisch, Winton Dennis Jones, Paul Leslie Ornstein, Hamid H. Zarrinmayeh, Dennis Michael Zimmerman
  • Publication number: 20040067984
    Abstract: The present invention provides compounds of formula (I): useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Application
    Filed: March 11, 2003
    Publication date: April 8, 2004
    Inventors: Buddy Eugene Cantrell, Winton Dennis Jones, Timothy Alan Shepherd, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Patent number: 6713516
    Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 12, 2002
    Date of Patent: March 30, 2004
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, David Michael Bender, Andrew Hendley Fray, Winton Dennis Jones, Paul Leslie Ornstein, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Patent number: 6693137
    Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: February 17, 2004
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, David Michael Bender, Buddy Eugene Cantrell, Winton Dennis Jones, Paul Leslie Ornstein, Richard Lee Simon, Edward C. R. Smith, Eric George Tromiczak, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Publication number: 20030225127
    Abstract: The present invention provides certain heterocyclic sulfonamide derivatives of formula (I): useful for potentiating glutamate receptor function in a patient and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Application
    Filed: April 1, 2003
    Publication date: December 4, 2003
    Inventors: David Michael Bender, Scott Louis Forman, Winton Dennis Jones, Daryl Lynn Smith, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Publication number: 20030225266
    Abstract: The present invention provides certain sulfonamide derivatives useful for potentiating glutamate receptor function in a patient and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Application
    Filed: August 15, 2002
    Publication date: December 4, 2003
    Inventors: Joshua Zwick Davison, Winton Dennis Jones, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Publication number: 20030220369
    Abstract: The present invention provides certain heterocyclic sulfonamide derivatives of formula I: useful for potentiating glutamate receptor function in a patient and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Application
    Filed: January 13, 2003
    Publication date: November 27, 2003
    Inventors: Scott Louis Forman, Winton Dennis Jones, Daryl Lynn Smith, Hamideh Zarrinmayeh, Dennis MIchael Zimmerman
  • Publication number: 20030171350
    Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Application
    Filed: December 12, 2002
    Publication date: September 11, 2003
    Inventors: MacKlin Brian Arnold, David Michael Bender, Andrew Hendley Fray, Winton Dennis Jones, Paul Leslie Ornstein, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Patent number: 6617351
    Abstract: The present invention provides certain amide, carbamate and urea derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: September 9, 2003
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, David Michael Bender, Thomas John Bleisch, Winton Dennis Jones, Paul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Patent number: 6525099
    Abstract: The present invention provides certain N-substituted sulfonamide derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: February 25, 2003
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, Winton Dennis Jones, Paul Leslie Ornstein, Hamideh Zarrinmayeh, Dennis Michael Zimmerman